ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1869

Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases

Shunya Kaneshita1, Christina Chambers2, Diana Johnson1, Arthur Kavanaugh1, Richard Garfein1 and Gretchen Bandoli1, 1University of California San Diego, La Jolla, CA, 2University of California, San Diego, La Jolla, CA

Meeting: ACR Convergence 2024

Keywords: COVID-19, Epidemiology, pregnancy, registry, Women's health

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Epidemiology & Public Health Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Pregnant women are particularly at risk of severe Coronavirus disease 2019 (COVID-19) infection, which is why the Centers for Disease Control and Prevention (CDC) recommends vaccination for pregnant women to prevent severe disease. Despite this recommendation, the frequency of adverse reactions to COVID-19 vaccination in pregnant patients with autoimmune inflammatory rheumatic diseases (AIIRD) remains unknown. We investigated the frequency of short-term (≤ 7 days) adverse reactions following COVID-19 vaccination in pregnant women with AIIRD.

Methods: A descriptive analysis of the incidence of side effects following COVID-19 vaccination in pregnant women with AIIRD was conducted using data from the MotherToBaby Study (MTB) registry, a prospective cohort study designed to assess the safety of drug and vaccine exposure during pregnancy. This study enrolled pregnant women living in the United States or Canada between January 2021 and September 2022.

Results: Of 1413 participants who received dose 1 of the COVID-19 vaccine during pregnancy, 79 had AIIRD. There was no significant difference in the total number of adverse reactions between pregnant women with and without AIIRD (β = –0.01, 95% CI: –0.17, 0.17). Pregnant women with higher HAQ-DI in AIIRD had a significantly higher total number of systemic reactions (β = 0.56, 95% CI: 0.04, 1.10) than those with lower HAQ-DI, although the total number of adverse reactions was not significantly different (β = 0.27, 95% CI: –0.08, 0.62). Users of DMARDs alone tended to experience fewer adverse reactions compared to those using both OCS and DMARDs or neither. (All reactions: mean (SD) of users of OCS and DMARDs = 2.75 (2.53), mean (SD) of users of DMARDs alone = 1.60 (1.33), mean (SD) of none users = 2.42 (2.50)).

Conclusion: We found no significant difference in the frequency of COVID-19 vaccine-related side effects between pregnant women with and without AIIRD. Patients with AIIRD who have higher levels of functional impairment may have a slightly higher frequency of short-term adverse effects. The results of this assessment may help provide information for pregnant women with AIIRD regarding COVID-19 vaccination.

Supporting image 1

Symptoms reported by women who received dose 1 of COVID_19 vaccine within 7 days

Supporting image 2

Symptoms reported by women with AIIRD who received dose 1 of COVID_19 vaccine within 7 days stratified by HAQ-DI

Supporting image 3

Symptoms reported by women with AIIRD who received dose 1 of COVID_19 vaccine within 7 days stratified by treatment


Disclosures: S. Kaneshita: None; C. Chambers: Amgen, 5, AstraZeneca, 5, Genzyme Sanofi-Aventis, 5, Gerber Foundation, 5, Gilead, 5, GlaxoSmithKlein(GSK), 5, Hoffman La-Roche-Genentech, 5, Janssen Pharmaceuticals, 5, Leo Pharma, 5, Novartis, 5, Pfizer, 5, Regeneron, 5, Sanofi, 5, Sun Pharma Global FZE, 5, Takeda Pharmaceutical Company Limited, 5, UCB Pharma, USA, 5; D. Johnson: Amgen, 5, AstraZeneca, 5, Genzyme Sanofi-Aventis, 5, Gerber Foundation, 5, Gilead, 5, GlaxoSmithKline, 5, Hoffman La-Roche-Genentech, 5, Janssen Pharmaceuticals, 5, Leo Pharma, 5, Novartis, 5, Pfizer, Inc., 5, Regeneron, 5, Sanofi, 5, Sun Pharma Global FZE, 5, Takeda Pharmaceutical Company Limited, 5, UCB Pharma, USA, 5; A. Kavanaugh: AbbVie, 2, Amgen, 2, BMS, 2, Janssen, 2, MoonLake Immunotherapeutics, 2, Novartis, 2, Pfizer, 2, Takeda, 2, UCB, 2, 5; R. Garfein: None; G. Bandoli: None.

To cite this abstract in AMA style:

Kaneshita S, Chambers C, Johnson D, Kavanaugh A, Garfein R, Bandoli G. Analysis of Short-Term Side Effects Following COVID-19 Vaccination in Pregnancies Complicated by Autoimmune Inflammatory Rheumatic Diseases [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/analysis-of-short-term-side-effects-following-covid-19-vaccination-in-pregnancies-complicated-by-autoimmune-inflammatory-rheumatic-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-short-term-side-effects-following-covid-19-vaccination-in-pregnancies-complicated-by-autoimmune-inflammatory-rheumatic-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology